Abstract
The use of biologic agents has revolutionized the management of rheumatoid arthritis (RA) in the past two decades. These biologic agents directly target molecules and cells involved in the pathogenesis of RA. Biologic agents indeed lead to a better prognosis and clinical remission in patients with RA, especially in patients who are not well-controlled with traditional disease-modifying anti-rheumatic drugs (DMARDs). Currently, five TNF inhibitors (infliximab, etanercept, adalimumab, golimumab and certolizumab pegol), an IL-6 receptor antagonist (tocilizumab), an IL-1 receptor antagonist (anakinra), a B cell depleting agent (rituximab) and a T cell co-stimulation inhibitor (abatacept) have been approved for the treatment of RA. With the increased understanding of the pathogenic mechanisms of RA and advantages in manufacturing biotechnology of pharmaceutical companies, a series of novel biologic therapeutic approaches are being developed. In the present paper, we will summarize the biologic agents currently available to treat RA, and the prospective biologic therapies that might be used in the management of RA in future.
Keywords: Biologic therapy, cell-targeted therapy, cytokine-targeted therapy, rheumatoid arthritis.
Current Pharmaceutical Biotechnology
Title:The Use of Biologic Therapies in the Treatment of Rheumatoid Arthritis
Volume: 15 Issue: 6
Author(s): Dashan Wang, Yan Li, Yuan Liu and Guixiu Shi
Affiliation:
Keywords: Biologic therapy, cell-targeted therapy, cytokine-targeted therapy, rheumatoid arthritis.
Abstract: The use of biologic agents has revolutionized the management of rheumatoid arthritis (RA) in the past two decades. These biologic agents directly target molecules and cells involved in the pathogenesis of RA. Biologic agents indeed lead to a better prognosis and clinical remission in patients with RA, especially in patients who are not well-controlled with traditional disease-modifying anti-rheumatic drugs (DMARDs). Currently, five TNF inhibitors (infliximab, etanercept, adalimumab, golimumab and certolizumab pegol), an IL-6 receptor antagonist (tocilizumab), an IL-1 receptor antagonist (anakinra), a B cell depleting agent (rituximab) and a T cell co-stimulation inhibitor (abatacept) have been approved for the treatment of RA. With the increased understanding of the pathogenic mechanisms of RA and advantages in manufacturing biotechnology of pharmaceutical companies, a series of novel biologic therapeutic approaches are being developed. In the present paper, we will summarize the biologic agents currently available to treat RA, and the prospective biologic therapies that might be used in the management of RA in future.
Export Options
About this article
Cite this article as:
Wang Dashan, Li Yan, Liu Yuan and Shi Guixiu, The Use of Biologic Therapies in the Treatment of Rheumatoid Arthritis, Current Pharmaceutical Biotechnology 2014; 15 (6) . https://dx.doi.org/10.2174/138920101506140910150612
DOI https://dx.doi.org/10.2174/138920101506140910150612 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MCP-1/CCL2 as a Therapeutic Target in Myocardial Infarction and Ischemic Cardiomyopathy
Inflammation & Allergy - Drug Targets (Discontinued) Soluble Adhesion Molecules in the Pathogenesis of Rheumatoid Arthritis
Current Pharmaceutical Design Active Tumor Targeting of Nanomaterials Using Folic Acid, Transferrin and Integrin Receptors
Current Drug Discovery Technologies The Long Pentraxin PTX3, a Soluble Pattern Recognition Receptor Involved in Innate Immunity,Inflammation and Female Fertility
Current Immunology Reviews (Discontinued) Two Key Challenges for Effective Adenovirus-Mediated Liver Gene Therapy:Innate Immune Responses and Hepatocyte-Specific Transduction
Current Gene Therapy HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Aliphatic and Aromatic Oxidations, Epoxidation and S-Oxidation of Prodrugs that Yield Active Drug Metabolites
Current Medicinal Chemistry Computational Development of Selective nNOS Inhibitors: Binding Modes and Pharmacokinetic Considerations
Current Medicinal Chemistry Targeting Strategies to Modulate the NF-κB and JNK Signal Transduction Network
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Role of B Cells in Multiple Sclerosis: Implications for B-Cell-Targeted Therapy
Current Medicinal Chemistry Regenerative Medicine: Does Erythropoietin have a Role?
Current Pharmaceutical Design Diagnostic Utility of Anti-Cyclic Citrullinated Peptide and Anti-Modified Citrullinated Vimentin Antibodies in Rheumatoid Arthritis
Protein & Peptide Letters Role of C-Reactive Protein in Acute Myocardial Infarction and Stroke: Possible Therapeutic Approaches
Current Pharmaceutical Biotechnology CCR1 Chemokine Receptor Antagonist
Current Pharmaceutical Design Novel High Throughput Polymer Biocompatibility Screening Designed for SAR (Structure-Activity Relationship): Application for Evaluating Polymer Coatings for Cardiovascular Drug-Eluting Stents
Combinatorial Chemistry & High Throughput Screening Natural Products Biosynthesis Involving a Putative Diels-Alder Reaction
Current Organic Chemistry Lymphoid-Specific Tyrosine Phosphatase (Lyp): A Potential Drug Target For Treatment of Autoimmune Diseases
Current Drug Targets Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease
Current Neuropharmacology “Multi-component Reactions : Emerging Chemistry in Drug Discovery” ‘From Xylocain to Crixivan’
Current Medicinal Chemistry Bone Diseases Associated with Human Immunodeficiency Virus Infection: Pathogenesis, Risk Factors and Clinical Management
Current Molecular Medicine